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Summary
 
Proteasomes generate peptides bound by major histocompatibility complex (MHC) class I
molecules. Avoiding proteasome inhibitors, which in most cases do not distinguish between
individual active sites within the cell, we used a molecular genetic approach that allowed for
the first time the in vivo analysis of defined proteasomal active sites with regard to their signifi-
cance for antigen processing. Functional elimination of the 
 
d
 
/low molecular weight protein
(LMP) 2 sites by substitution with a mutated inactive LMP2 T1A subunit results in reduced cell
surface expression of the MHC class I H-2L
 
d
 
 and H-2D
 
d
 
 molecules. Surface levels of H-2L
 
d
 
 and
H-2D
 
d
 
 molecules were restored by external loading with peptides. However, as a result of the
active site mutation, MHC class I presentation of a 9-mer peptide derived from a protein of
murine cytomegalovirus was enhanced about three- to fivefold. Our experiments provide evi-
dence that the 
 
d
 
/LMP2 active site elimination limits the processing and presentation of several
peptides, but may be, nonetheless, beneficial for the generation and presentation of others.
Key words: proteosome • antigen processing • mutation • active site • low molecular weight
protein 2 T1A
 
U
 
sing proteasome-specific inhibitors, the proteasome
system has been shown to be involved in antigen pro-
cessing and to represent the major source for the generation
of MHC class I peptides (1–4). The 20S proteasome is an
NH
 
2
 
-terminal nucleophile hydrolase possessing an active
site threonine residue (5). It is a cylinder-shaped particle
composed of four stacked rings of seven subunits each. In
eukaryotes, the seven different 
 
a
 
 type subunits occupy po-
sitions in the two outer rings, whereas the two inner rings
are formed by seven different 
 
b
 
 type subunits (6). The pro-
teolytic activity is restricted to the lumen of the cylinder and
is mediated by three of the seven 
 
b
 
 type subunits, i.e., subunits
 
d
 
 (
 
b
 
1), MB1 (
 
b
 
5), and Z (
 
b
 
2) (parentheses, new nomen-
clature according to Groll et al., reference 7). Therefore, in
total, the 20S proteasome complex possesses six active sites
within the two inner 
 
b
 
 rings. By induction with the cyto-
kine IFN-
 
g
 
, the active site bearing constitutive 
 
b
 
 subunits
are replaced by their IFN-
 
g
 
–inducible counterparts low
molecular weight protein 2 (LMP2)
 
1
 
 (i
 
b
 
1), LMP7 (i
 
b
 
5),
and MECL-1 (i
 
b
 
2) during proteasome assembly (3, 8, 9).
Of these, LMP2 (i
 
b
 
1) and LMP7 (i
 
b
 
5) are encoded within
the MHC class II region in the direct neighborhood of the
TAP1 and TAP2 peptide transporter genes (10, 11).
MECL-1 (i
 
b
 
2) is encoded outside the MHC locus, but its
incorporation into the 20S proteasome complex is guaran-
teed through the presence of LMP2 (i
 
b
 
1; reference 12).
The IFN-
 
g
 
–induced replacement of subunit 
 
d
 
 (
 
b
 
1) by
LMP2 (i
 
b
 
1), subunit MB1 (
 
b
 
5) by LMP7 (i
 
b
 
5), and Z (
 
b
 
2)
by MECL-1 (i
 
b
 
2) results in changes of the hydrolytic ac-
tivities as monitored with short fluorogenic peptide sub-
strates (13, 14). In addition, the incorporation of these sub-
units strongly alters the cleavage site preferences of the 20S
proteasome in vitro (14, 15). As a consequence, a different
set of peptides products is generated by the 20S protea-
some. Under physiological conditions, the ratio between
constitutive and cytokine-modified proteasomes complexes
changes only slowly. Accordingly, the abundance of certain
peptide products as well as their quality will gradually
change during the time course of IFN-
 
g
 
 induction. Indeed,
targeted deletion of LMP2 (i
 
b
 
1) and LMP7 (i
 
b
 
5) in mice
caused alterations in antigen presentation, emphasizing the
importance of these subunits for the generation of at least
certain MHC class I antigens (16, 17). Using proteasome
 
1
 
Abbreviations used in this paper:
 
 LMP, low molecular weight protein;
MCA, amido-4-methylcoumarin; MCMV, murine CMV.
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inhibitors, it has been shown that the inhibition of some of
the proteasomal peptidase activities affects the processing of
MHC class I antigens. (1, 18). However, there exists little
active site specificity of the available proteasome aldehyde
inhibitors. Even the active site specificity of lactacystin
demonstrated in vitro is difficult to control in cell experi-
ments since, depending on the experimental condition, lac-
tacystin affects more than one type of active site (19, 20).
Therefore, experimental setups using proteasome inhibitors
in most cases do not allow one to draw any conclusions on
the functional importance of a specific active site for the
generation of a defined MHC class I antigen. Such knowl-
edge is, however, important to better understand the basic
rules of antigen processing and to develop strategies that
may allow either up- or downregulation of the generation
of a defined antigenic peptide.
To overcome these problems, we made use of a recently
described mutation in the nonconstitutive LMP2 (i
 
b
 
1) sub-
unit in which the NH
 
2
 
-terminal active site threonine was
replaced by alanine (21). This T1A mutation resulted in the
impairment of correct maturation by autocatalytic process-
ing of the subunit and rendered an proteolytically inactive
LMP2 subunit. In this study, we used the inactive mutant
to study the functional importance of the 
 
d
 
/LMP2 (
 
b
 
1/
i
 
b
 
1) active sites with regard to MHC class I antigen presen-
tation. Overexpression of the mutant LMP2 T1A subunit
in mouse fibroblast cells resulted in an effective replace-
ment of the proteolytically active 
 
d
 
 (
 
b
 
1) subunit. As a con-
sequence, the mutant LMP2 T1A cells contain proteasomes
in which two of the six active sites of the 20S proteasome
complex are eliminated. Our experiments demonstrate that
the deletion of these active sites generally limits the pro-
duction of peptides bound to H-2L
 
d
 
 and H-2D
 
d
 
 molecules.
At the same time, the mutation enhances the generation
and presentation of an H-2L
 
d
 
 epitope derived from the cy-
tomegalovirus pp89 protein.
 
Materials and Methods
 
Cell Lines.
 
The BALB/c-derived mouse fibroblast cell lines
C4 and B8 were used. The B8 cell line, which is derived from
the C4 cells, constitutively expresses the IE I pp89 of the murine
cytomegalovirus (22). The B8 cell line was subcloned by limiting
dilution and one clone was chosen as recipient for the transfection
experiments. The generation of the cDNA constructs of LMP2
and LMP2 T1A, transfection by conventional calcium phosphate
precipitation and selection are described in detail in reference 21.
 
Purification of 20S Proteasomes and Assay of Proteolytic Activity.
 
20S proteasomes were purified using standard procedures (21).
V
 
max
 
 and 
 
K
 
m
 
 values were determined using the fluorogenic peptide
substrates Bz-Val-Gly-Arg-7 Amido-4-methylcoumarin (MCA),
Z-Gly-Gly-Leu-MAC, Suc-Leu-Leu-Val-Tyr-MCA, and Meth-
oxysuccinyl-Gly-Leu-Phe-MCA (Bachem, Heidelberg, Germany).
The peptides were used in concentrations from 5 to 200 
 
m
 
M and
incubated with 1 
 
m
 
g/ml proteasome in 200 
 
m
 
l of 50 mM Tris-
HCl, pH 7.5, 25 mM KCl, 10 mM NaCl, and 0.1 mM EDTA (assay
buffer) for 1 h at 37
 
8
 
C as described before (14). Fluorescence in-
tensity was measured at an excitation wave length of 390 nm and an
emission wave length of 460 nm in a SLT Fluostar spectrofluorome-
ter. Data were analyzed according to Lineweaver and Burk. All
assays were performed in triplicate and repeated three times.
 
Western Blotting.
 
15 ng of purified proteasomes were sepa-
rated by SDS-PAGE and blotted as described (21). The blots
were incubated with either LMP2- or 
 
d
 
-reactive antisera. Immu-
noreactive proteins were detected by enhanced chemilumines-
cence.
 
Northern Analysis.
 
The poly A
 
1
 
 mRNA of the cell lines C4,
B8, B8-LMP2, control, and B8-LMP2 T1A was prepared using
commercially available kits (Quiagen, Darmstadt, Germany). 3 
 
m
 
g
of mRNA was applied to each lane. Agarose gel electrophoresis,
blotting, labeling of the cDNA fragments, and hybridization was
performed according to standard procedures (23). We used three
different cDNA fragments simultaneously, a PstI/HindIII frag-
ment (bp 297–815), a HindIII/PstI fragment (bp 815–1,314), and
a PstI to 3
 
9
 
 fragment (bp 1,314–1,788). After hybridization and
washing the blot was quantitated and visualized with a Phosphor-
Imager (Molecular Dynamics, Krefeld, Germany).
 
Flow Cytometry.
 
Cells were removed from culture dishes
with calcium- and magnesium-free medium, washed, and stained
according to standard protocols with the monoclonal antibodies
19/191 (anti–H-2D
 
d
 
), 3-25.4 (anti–H-2D
 
d
 
; PharMingen, San Di-
ego, CA), 28-14-8S (anti–H-2L
 
d
 
), 28-14-8 (anti–H-2L
 
d
 
; Phar-
Mingen), and 15-5-5S (anti–H-2K
 
d
 
), and a sheep anti–mouse
F(ab)2–FITC conjugate as a second-stage reagent. The analysis
was performed with a FACSCAN
 
Ò
 
 
 
flow cytometer and LYSIS
II
 
Ô
 
 
 
software (Becton Dickinson, Heidelberg, Germany).
 
Acid Elution of Natural Peptides and MHC Class I Peptide Binding
Assay.
 
For peptide extraction and external-loading peptides we
followed the procedure as described previously (24, 25). B8 cells
(2 
 
3 
 
10
 
9
 
) were separated from the culture dishes with calcium-
and magnesium-free medium and washed with PBS to remove
serum proteins. The cells were incubated for 15 min on ice in
0.1% TFA/H
 
2
 
O, sonicated, and kept on ice for another 15 min.
Cells were centrifuged for 15 min at 15,000 rpm and the superna-
tant was collected. High molecular mass material was removed by
centrifugation at 4
 
8
 
C through a 10-kD Centricon filter (Amicon
Corp., Easton, TX). The peptides were concentrated by Speed
Vac centrifugation to a final concentration of 
 
z
 
5 mg/ml as judged
by OD 280. B8 cells and the transfectants were cultured for 18 h
at 27
 
8
 
C in the presence of either 25 
 
m
 
g/ml of the synthetic pep-
tide YPHFMPTNL (H-2L
 
d
 
 epitope of pp89) or 
 
z
 
25 
 
m
 
g/ml of
peptides extracted from B8 cells by acidic elution. Cells were re-
moved from culture dishes with calcium- and magnesium-free
medium and incubated at a density of 10
 
6
 
 /ml for 1 h on ice in
PBS containing the peptides in concentrations as described above.
After 1 h, cells were resuspended in serum-free medium contain-
ing the peptides and left for 2 h at 37
 
8
 
C at a density of 2 
 
3 
 
10
 
5 
 
/ml.
Staining of the surface level of MHC class I molecules was per-
formed as described above.
 
Cytolytic Assays.
 
Target cells for cytolytic assays were labeled
for 90 min with Na
 
2
51
 
CrO
 
4
 
. A standard 4-h cytolytic assay was
performed in triplicate with 1,000 target cells and the indicated
numbers of effector cells in two- or fourfold dilution steps as de-
tailed in reference 26. All experiments were performed three
times in triplicate cultures with two clones of each transfectant,
except for the LMP2 T1A transfectant where four clones were
analyzed.
 
Results and Discussion
 
Efficient Incorporation of the LMP2 T1A Subunit into the
20S Proteasomes.
 
To investigate the consequence of a de- 
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fined active site elimination in the mouse 20S proteasome
complex, the murine fibroblast cell line B8 was stably
transfected with cDNAs either encoding a wild-type LMP2
or a mutated LMP2 subunit in which the active site threo-
nine 1 residue was exchanged against alanine by site-directed
mutagenesis (21). Overexpression of the LMP2 or LMP2
T1A subunits results in efficient incorporation of these sub-
units into the 20S proteasome complex (Fig. 1). The incor-
poration of the LMP2 proteins is associated with an almost
complete exchange against subunit 
 
d
 
. Accordingly, by im-
munoblotting with anti-
 
d
 
 antibody only after overexposure
of the enhanced chemiluminescence blot, negligible amounts
of residual 
 
d
 
 subunit could be identified in 20S proteasomes of
B8-LMP2 and B8-LMP2 T1A cells. The slower electro-
phoretic mobility of LMP2 T1A also demonstrates that the
NH
 
2
 
-terminal prosequence is only partially cleaved, resulting
in an NH
 
2
 
-terminal extension of the subunit. Thus, over-
expression of both the functional LMP2 subunit and the
LMP2 T1A active site mutant subunit and the concomitant
elimination of the active site bearing 
 
d
 
 subunit from the
20S proteasome complexes allows production of a B8 cell
line whose proteasome population possesses only four, in-
stead of six, active sites. Interestingly, the functional elimi-
nation of this active site had no obvious phenotypic effect
on the B8 fibroblast cells and appeared not to affect their
growth rate.
 
Active Site Mutation Influences the Proteolytic Activity of 20S
Proteasomes In Vitro.
 
The effect of the active site mutation
on the proteolytic activities of the 20S proteasome was
tested by analyzing the peptide-hydrolyzing activities of
20S proteasomes from B8, B8-LMP2, and B8-LMP2 T1A
with short fluorogenic peptide substrates (Table 1). Inde-
pendent of the substrates used, neither the substitution of
subunit 
 
d
 
 by LMP2 nor the elimination of this active site
by incorporation of LMP2 T1A has a significant effect on
the V
 
max of the 20S proteasome. This holds true for the
trypsin-like activity monitored with the substrate Bz-Val-
Gly-Arg-MCA as well as for the chymotrypsin-like activity
measured with Z-Gly-Leu-Leu-MCA and Suc-Leu-Leu-
Val-Tyr-MCA. Only in using MeOsuc-Gly-Leu-Phe-
MCA was a reduction in Vmax by a factor of 2.9 measured
in the B8-LMP2 T1A mutant. Also, the Km value, the
measure for the binding affinity of substrates, was only
moderately influenced by subunit substitution or active site
mutation. For all substrates, we monitored an approxi-
mately twofold increase in the Km for the LMP2 T1A pro-
teasome. One possible reason for the observed increase in
Km values in the LMP2 T1A mutant could be that the
NH2-terminal extension of 8–10 amino acids of the mutant
subunit influences the accessibility of the other active sites
and hence the substrate binding affinity. Apart from this,
the data suggest that the active site under investigation has
little effect upon the trypsin and chymotrypsin-like peptide
substrates, which is in agreement with the previous finding
that the d/LMP2 site affects the peptidyl glutamyl peptide-
hydrolyzing activity (PDGH activity) of the proteasome
complex. This activity is completely eliminated in these
cells (data not shown). On the other hand, these data show
that the different hydrolyzing activities, as monitored with
unphysiologically short substrates, are in fact overlapping
and that the attractive model of three different proteolytic
specificities each mediated by one of three pairs of active
sites is perhaps too simple. In a recent investigation, Eleu-
teri and coworkers (27) came to a similar conclusion by
showing that short peptide hydrolyzing activities are over-
lapping and that different active sites cleave more than one
type of short fluorogenic substrate. Interestingly, the incor-
poration of the LMP2 subunit into 20S proteasomes as such
and not its activity seems to affect the enzymatic character-
istics of the active sites of the neighboring subunit Z (b2)
and the more distant subunit MB1(b5). This suggests once
more (14) that the incorporation of this IFN-g–inducible
subunit may also influence the structure function relation-
ship within the proteasome complex.
Active Site Deletion Leads to Reduced Surface Levels of MHC
Class I Alleles. To investigate the effect of the d/LMP2
active site mutation on the generation of antigenic peptides
Figure 1. Expression of either
LMP2 or the mutant LMP2 T1A
results in complete replacement
of subunit d in 20S proteasomes.
20S proteasomes purified from
the cell line B8 and from LMP2–,
control–, and LMP2 T1A–trans-
fected cells were examined for
the presence of subunit d ( top)
and LMP2 (bottom) by Western
blotting. Even after strong over-
exposure of the immunoblots,
only negligible amounts of resid-
ual d subunit can be identified in
20S proteasomes of B8-LMP2
and B8-LMP2 T1A cells. Arrows,
the position of a 21-kD marker
protein.
Table 1. Effects of Transfection of Wild-type B8 Cells with LMP2 
and LMP2 T1A cDNAs on the Peptidase Activities of Proteasomes
Substrate
B8 B8-LMP2 B8-LMP2 T1A
Vmax Km Vmax Km Vmax Km
mmol/h mg mM mmol/h mg mM mmol/h mg mM
VGR-MCA 0.31 57 0.31 76 0.35 100
GGL-MCA 0.85 25 0.79 33 0.75 52
LLVY-MCA 1.11 29 1.20 41 1.33 70
GLF-MCA 0.18 35 0.14 35 0.05 83
Vmax and Km values were determined with 20S proteasomes and the
substrates Bz-Val-Gly-Arg-AMC for the trypsin-like activity, Z-Gly-Gly-
Leu-MCA, Suc-Leu-Leu-Val-Tyr-MCA, and MeOsuc-Gly-Leu-Phe-
MCA for the chymotrypsin-like activity. The peptidyl-glutamyl-peptide
hydrolyzing activity measured with the substrate Cbz-Leu-Leu-Glu-
bNa was undetectable in both B8-LMP2 and B8-LMP2 T1A transfec-
tants and is therefore not shown.1644 Proteasome Mutation by Site-directed Mutagenesis Affects Antigen Presentation
in vivo, we analyzed the cell surface expression of MHC
class I molecules whose assembly and efficient transport to
the cell surface is dependent on the loading with suitable
peptides. Flow cytometric analysis of several independent
B8-LMP2 T1A cell clones with allele-specific antibodies
revealed an z40% reduction in the cell surface expression
of the H-2Dd and H-2Ld molecules when compared with
B8, B-LMP2, or B8 mock-transfected control cells (Fig. 2).
No difference in cell surface expression was found for the
H-2Kd molecules (data not shown). That this is not a clonal
effect is demonstrated by the finding that identical data
were obtained with different B8-LMP2 T1A cell lines.
These results suggest that the elimination of the two active
sites restricts the overall quality of peptide generated, thus
possibly limiting the supply of peptide and, in conse-
quence, negatively affecting MHC class I molecule assem-
bly and cell surface expression.
To test this hypothesis we took advantage of the obser-
vation that MHC class I molecules can reach the cell’s sur-
face without prior peptide binding when cells are incu-
bated at 278C and that empty MHC class I molecules can
be stabilized by binding of externally added peptides (24,
25). B8-LMP2 T1A cells were therefore loaded either with
a synthetic 9-mer peptide that binds to H-2Ld or peptides
extracted from B8 cells. As expected from its binding char-
acteristics, the synthetic 9-mer peptide restores the level of
H-2Ld, but not that of H-2Dd on B8-LMP2 T1A cells (Fig.
3 C). Furthermore, peptides extracted from nontransfected
B8 cells were able to stabilize the levels of both MHC al-
leles on the surface of B8-LMP2 T1A cells (Fig. 3 D).
These data demonstrate that it is indeed the lack of peptides
that is responsible for reduced MHC class I expression on
the surface of B8-LMP2 T1A cells. In support of this, pulse
chase experiments and immunoprecipitation of H-2Dd and
Figure 2. Active site mutation results in decreased surface levels of
H-2Ld and H-2Dd alleles. Analysis of surface expression of the MHC class
I molecules H-2Ld and H-2Dd by flow cytometry. Logarithmic fluores-
cence is plotted versus cell count. neg. con., the second stage control only.
Shown are the histograms of the stainings of B8 (A), of the LMP2 trans-
fectant (B), and of B8 transfected with control vector (C). Also, several
different clones of the LMP2 T1A transfectants were tested; the presented
data of the clones LMP2 T1A B5 (D), LMP2 T1A E7 (E), and LMP2
T1A A2 (F) show a 40% reduction of H-2Ld and H-2Dd expression.
Identical results were obtained in all independent experiments performed
with two different anti–H-2Ld and anti–H-2Dd antibodies.
Figure 3. Reconstitution of surface expression of MHC class I on B8-
LMP2 T1A cells by externally added peptides. Analysis of surface expres-
sion of the MHC class I molecules H-2Ld and H-2Dd by flow cytometry.
Logarithmic fluorescence is plotted versus cell count. Curves drawn by
thin lines represent the second stage control. Cells were cultured 18 h at
278C in the presence of acid extracted peptides or a synthetic 9-mer
known to bind H-2Ld. (A) Histograms of B8 cells (control) incubation
with peptides does not alter MHC expression. (B) LMP2 T1A–trans-
fected cells incubated in the absence of external peptides. (C) B8-LMP2
T1A cells incubated in the presence of a synthetic 9-mer known to bind
to H-2Ld molecules. H-2Ld expression increases, whereas H-2Dd is not af-
fected. (D) The externally added peptides from B8 cells restore the surface
expression of MHC class I molecules on B8-LMP2 T1A cells.1645 Schmidtke et al.
H-2Ld molecules showed that these molecules are equally
well expressed in all cell lines analyzed (data not shown). It
may be argued that reduced temperatures can increase
MHC expression independent of peptide supply. How-
ever, under the same experimental conditions, the number
of Kd molecules does not increase at the cell surface at
278C, even when peptides extracted from B8 cells are ex-
ternally loaded.The elimination of active sites in the 20S
proteasome complex therefore decreases the general
amount of peptides available for binding to MHC class I
H-2Dd and H-2Ld molecules. In contrast, the level of H-2Kd
molecules is not reduced. Interestingly, all three haplotypes
possess similar preferences for the COOH-terminal anchor
residue but differ with regard to the residue preference at
position 2 of the epitope. This indicates that the functional
importance of the activity of the d/LMP2 varies depending
on the type of peptide products that have to be generated
for binding to a given MHC class I haplotype. In addition,
despite the fact that the peptide hydrolyzing activities of
the different active sites of the 20S proteasome are overlap-
ping as deduced from in vitro data obtained with short flu-
orogenic peptide substrates (27), the d/LMP2 active sites
exert a specific cleavage property that is responsible for the
in vivo generation of a specific peptide quality from natural
protein substrates.
Enhanced Specific Cytolysis of Cells Expressing the LMP2
T1A Protein. So far the experiments showed that the
functional elimination of two defined active sites in the 20S
proteasome complex affects the quality of peptide genera-
tion and results in the downregulation of certain, but not
all, MHC class I molecules. To determine how far the ac-
tive site mutation influences the presentation of a specific
peptide, we analyzed the different transfectant B8 cell lines
with regard to their ability to present an immunodominant
9-mer peptide of the murine CMV (MCMV) pp89 to a
H-2Ld–specific T cell line in a cytotoxicity assay. As shown
in Fig. 4, B8 cells and B8 control–transfectant cells were
lysed to the same extent, whereas B8-LMP2 cells were
slightly less susceptible to lysis. In contrast, three- to five-
fold less pp89/H-2Ld–specific cytotoxic T cells were re-
quired to lyse the B8-LMP2 T1A cells.
To exclude the possibility that increased pp89 expression
in B8-LMP2 T1A cells was responsible for the observed ef-
fect, we investigated the expression of pp89 by Northern
blot analysis since pp89 is quite stable at the posttransla-
tional level (22). As shown in Fig. 4 B, no significant differ-
ences in the expression of pp89 can be detected in the in-
vestigated cell lines. Thus, despite the elimination of two
active sites, sufficient pp89 antigen is generated to allow an
increase in peptide-specific MHC class I presentation. Al-
though in vitro experiments do not necessarily reflect the
in vivo situation, it is interesting to note that in vitro diges-
tions experiments of the pp89 25-mer synthetic polypep-
tide harboring the 9-mer epitope (15) show that the im-
proved MHC class I presentation may be due to altered
proteasomal processing properties. Although d/LMP2 pro-
teasomes have the tendency to destroy the epitope, mutant
LMP2 T1A proteasomes do not use the internal cleavage
site and thus seem to preserve the epitope (Ruppert, T.,
unpublished observations). In consequence, the increased
maximum of lysis observed may be due to an increase in
specific peptide supply. Considering that the overall H-2Ld
surface expression is reduced in B8-LMP2 T1A cells, these
experiments represent the first example that the specific
elimination of a proteasomal active site, in this case d/LMP2,
may be beneficial for presentation of certain class I epitopes,
despite reduced MHC class I expression.
Figure 4. Active site mutation leads to enhanced presentation of the
pp89 MCMV 9-mer peptide. (A) Analysis of MCMV pp89 antigen pre-
sentation in the cell lines B8 (white squares), LMP2 (black diamonds), con-
trol (white circles), and LMP2 T1A (white triangles). The susceptibility to ly-
sis by MCMV pp89 (amino acids 168–176/H-2Ld) -specific cytotoxic T
cells was determined in a 4-h chromium release assay. Effector/target ra-
tios are plotted versus the percent of specific lysis. Values represent the
means of three replicate cultures. Identical results were obtained in four
independent experiments with two different B8-LMP2 clones and three
different B8-LMP2 T1A clones. (B) Northern blot analysis of mRNA ex-
pression of the MCMV IE-I protein pp89. C4 is a BALB/c mouse-derived
fibroblast cell line from which B8 was obtained by transfection with the
pp89 cDNA. B8 cells were stably transfected with the LMP2 cDNA ex-
pression construct (LMP2), vector only (control), or with a construct ex-
pressing the mutated cDNA of LMP2 (LMP2 T1A). Blotted poly A1
mRNA prepared from C4, B8, B8-LMP2, control, and B8-LMP2 T1A
was hybridized with a pp89 cDNA probe. All cell lines contain almost
identical amounts of pp89 mRNA according to PhosphorImager analysis.
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